PREFER (IMI)
Eliciting patient preferences on benefits/risks of medicines
PREFER is a 5-year project, partly funded by IMI. It aims to investigate methodologies to elicit informed patient preferences regarding the benefit/risk of drugs, from drug development through the entire life cycle, to inform the decision-making process by regulators and HTA bodies.
Expertise in online learning
MindBytes’ contribution to this project is to use our expertise in online learning to develop an evidence-based e-learning as a methodology for patient preference elicitation and health utility assessment. The educational tool should allow us to:
- Inform patients about the true trade-offs involved with the benefits-risks associated to medicines, both short term and long term
- Assess which trade-offs patients make (patient preferences)
Cognitive and behavioral profiles
The complete tool incorporates concepts like Discrete Choice Experiments (DCE), Best-Worst Scaling (BWS) and conjoint analysis. It captures patient’s cognitive and behavioral profiles to allow for stratification in patient sub-groups. It aligns with NICE & Health Economic standards.
Partners
Uppsala University
Newcastle University
Erasmus UMC
UMC Utrecht
KU Leuven
European Institute Oncology
Muscular Dystrophy UK
Novartis
Roche
Sanofi
Takeda
Pfizer
Various other
